Takeda in Pact for Needle-Free Drug Delivery
Takeda Pharmaceutical Company and Portal Instruments, a Cambridge, Massachusetts-based medical equipment manufacturer, have agreed to develop and commercialize Portal’s needle-free drug delivery device for potential use with Takeda’s investigational or approved biologic medicines.
Portal’s needle-free drug-delivery device delivers the biologic through a pressurized liquid instead of a needle. The needle-free device is designed to be self-administered by patients at home. The device was developed at the Massachusetts Institute of Technology.
The first Takeda development program to use this device will be for investigational use with Entyvio (vedolizumab), a monoclonal antibody for treating adults with moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD), which is currently administered through intravenous infusion. A Phase III clinical trial program is currently evaluating the efficacy and safety of a subcutaneous formulation of vedolizumab in adults with moderately to severely active UC or CD.
Under the agreement, Portal will receive an initial payment with the potential to earn additional payments of up to $100 million subject to achievement of specified development, regulatory, and sales-based milestones and royalties.
Source: Takeda Pharmaceutical